Full-Time

Senior Director of Training and Learning Excellence

Commercial

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$245k - $275k/yr

+ Bonus + Equity

Palo Alto, CA, USA + 1 more

More locations: San Francisco, CA, USA

Hybrid

Hybrid role; in-office 2-3x per week in SF and Palo Alto; travel ~20%.

Category
Training
Required Skills
Branding/Brand Strategy
Requirements
  • BA/BS required; advanced degree preferred
  • 10+ years of experience in commercial or medical functions within the Biotech/Pharma industry, field sales experience is a plus (not required)
  • 5+ years of experience in training leadership, experience in field team training preferred
  • Proven track record of effectively collaborating with and strategically supporting a Leadership team
  • Experience aligning strategic needs with curriculum/content development, navigating promotional review process, training and administration of Learning Management Systems
  • Ability to work in a fast-paced environment, meet short deadlines, and collaborate with cross-matrix teams and affiliate stakeholders
  • Exceptional clinical insight and ability to grasp complex scientific topics across therapeutic areas
  • Excellent facilitation, platform, written and verbal communication skills
  • Exhibit passion and empathy to build meaningful experiences for trainees by understanding their needs and learning styles
  • Proactive, results-oriented self-starter motivated by a challenging task and ability to manage multiple priorities in a fast-paced environment
  • Strong vendor management and internal review/negotiation experience
  • Other: Commitment to comply with all laws, regulations, and relevant policies that govern the conduct of BridgeBio activities
  • Travel approximately 20%
Responsibilities
  • Establish an “industry-best” training department dedicated to BridgeBio organizational learning objectives, customized to develop knowledge, skills, and behaviors specific to affiliate customer and business needs
  • Oversee learning needs assessment in collaboration with the business owners (BridgeBio Affiliate Partners) to clearly understand and define the gaps in skills and knowledge
  • Lead the definition and implementation of the most effective learning mix (i.e., live/virtual instructor-led, e-learning, blended learning, social learning) for the agreed target audience with best practices and principles of instructional design
  • Lead the creation and standardization of Launch Excellence models for new products/indications from early planning to post-launch sustainment
  • Oversee the development and facilitation of engaging and interactive workshops on disease states, products, marketplaces, and contextual selling skills for all types of audiences
  • Ensure the strategic utilization of resources by overseeing the identification and selection of vendors as well as existing relationships and projects relating to training (SOW and PO generation and vendor management)
  • Participate in the annual business planning process and lead resource allocation and budgeting
  • Contribute to the implementation of the training curriculum to strategically support our growing organization, building clinical product and market knowledge, as well as the communication skills required to effectively engage health care professionals (HCPs) and execute brand strategies
  • Develop and establish training initiatives that build deep clinical expertise and translate strategy into actionable behaviors
  • Proactively partner with Marketing, Market Access, Medical Affairs, and Clinical Development to identify knowledge gaps and work with functional leaders to address them
  • Collaborates with corporate/global learning and development partners to identify synergies and leverage resources collectively
  • Ensure training initiatives are effective and compliant with regulatory guidelines through collaboration with functional partners, including Medical, Regulatory, and Legal/Compliance

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Your Connections

People at BridgeBio who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Acoramidis commercialization is expanding into Australia, Singapore, South Korea, and Taiwan.[1]
  • Encaleret's NDA filing creates a near-term regulatory catalyst for ADH1.[7]
  • BBP-418 Phase 3 progress strengthens diversification beyond Attruby.[7]

What critics are saying

  • Attruby concentration leaves BridgeBio dependent on one marketed product.[7]
  • Encaleret still faces FDA rejection, delay, or a complete response letter.[7]
  • BridgeBio's losses and capital raises create ongoing dilution pressure.[3][7]

What makes BridgeBio unique

  • BridgeBio uses a decentralized hub-and-spoke model for rapid rare-disease development.[4][7]
  • Its pipeline spans approved, late-stage, and early-stage programs across 48 indications.[4][7]
  • The company targets genetically defined diseases with clear root-cause biology.[1][4][8]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.